Novartis Expands Neuromuscular Pipeline with $12B Acquisition
Kilder
- Statnews: Novartis to buy RNA-focused Avidity in $12 billion deal - statnews.com
- Biopharmadive: Novartis to acquire Avidity in $12B bet on RNA drugs for neuromuscular disease - BioPharma Dive
- Biospace: UniQure’s Huntington’s Breakthrough Brings Hope to Patients but Experts Urge Caution - BioSpace
- Biospace: 4 Huntington’s Therapies Chasing UniQure - BioSpace
- Biospace: Novartis To ‘Bolster’ Neuromuscular Pipeline With $12B Avidity Acquisition - BioSpace
- Biospace: Coya Exec Daniel Barvin Is on a Mission To End Genetic ALS and FTD - BioSpace
Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.